Pfizer Funds Anti-Blindness Treatment

Branch Jr., Al
February 2003
Pharmaceutical Executive;Feb2003, Vol. 23 Issue 2, p28
Trade Publication
Reports on the partnership between Pfizer Inc. and Eyetech Pharmaceutical for a drug development in the U.S. Medication to treat age-related macular degeneration; Insurance coverage for the medicine; Investment of Pfizer Inc. for the drug development.


Related Articles

  • Pfizer, Eyetech in deal for AMD, DME therapy.  // Ophthalmology Times;2/1/2003, Vol. 28 Issue 3, p6 

    Reports on the deal between Pfizer Inc. and Eyetech Pharmaceuticals Inc. to develop and commercialize pegaptanib sodium Macugen in the U.S. Terms of the deal; Sales projected by Eyetech upon approval of the drug; Responsibility to Pfizer to finance the manufacturing cost of the drug.

  • Eyetech sales force to offer Pfizer's latanoprost.  // Ophthalmology Times;6/1/2003, Vol. 28 Issue 11, p4 

    Reports on the help offered by the sales force of Eyetech Pharmaceuticals Inc. to sell the latanoprost ophthalmic solution of Pfizer Inc. to ophthalmologists in the U.S.

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...

  • Mergers & Acquisitions Update.  // PharmaWatch: Biotechnology;Oct2005, Vol. 4 Issue 10, p16 

    The article presents information about the latest mergers and acquisitions in the biotechnology industry. It is reported that Pfizer Inc. has reached an agreement to acquire Bioren, a California-based firm specializing in technology for optimizing antibodies, for an undisclosed amount. Antibody...

  • Macugen account goes to Medicus. Arnold, Matthew // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p10 

    Reports that Pfizer and Eyetech Pharmaceuticals have appointed Medicus New York to handle professional advertising for their co-marketed Macugen drug for macular degeneration. Account is Medicus Group's first formal assignment from Pfizer; Parent firm Publicis Groupe's work with Pfizer in the...

  • Retina Specialists: A Grim View of AMD.  // Review of Ophthalmology;Aug2004, Vol. 11 Issue 8, p12 

    Presents results from the online survey regarding wet age-related macular degeneration (AMD), commissioned by the Eyetech Pharmaceuticals and Pfizer, in consultation with the Lighthouse International. Percentage of specialists who were alarmed by the increasing number of cases of wet AMD; Effect...

  • Research.  // Journal of Visual Impairment & Blindness;Jan2005, Vol. 99 Issue 1, p55 

    Reports on the approval received by Eyetech Pharmaceutical and Pfizer for the eye treatment Macugen. Benefits of Macugen for patients; Eye disease that can be treated by the drug.

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics